These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 28130773)

  • 1. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
    Trippe ZA; Brendani B; Meier C; Lewis D
    Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.
    Martin D; Menschik D; Bryant-Genevier M; Ball R
    Drug Saf; 2013 Jul; 36(7):547-56. PubMed ID: 23657824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites.
    Juhlin K; Karimi G; Andér M; Camilli S; Dheda M; Har TS; Isahak R; Lee SJ; Vaughan S; Caduff P; Norén GN
    Drug Saf; 2015 Apr; 38(4):373-82. PubMed ID: 25687792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker.
    Berlin C; Blanch C; Lewis DJ; Maladorno DD; Michel C; Petrin M; Sarp S; Close P
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):622-30. PubMed ID: 21994119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.
    Bailey S; Singh A; Azadian R; Huber P; Blum M
    Drug Saf; 2010 Feb; 33(2):139-46. PubMed ID: 20082540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study.
    Pozsgai K; Szűcs G; Kőnig-Péter A; Balázs O; Vajda P; Botz L; Vida RG
    Front Pharmacol; 2022; 13():964399. PubMed ID: 36147337
    [No Abstract]   [Full Text] [Related]  

  • 7. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
    Castillon G; Salvo F; Moride Y
    Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suspected poor-quality medicines in Kenya: a retrospective descriptive study of medicine quality-related complaints reports in Kenya's pharmacovigilance database.
    Toroitich AM; Armitage R; Tanna S
    BMC Public Health; 2024 Sep; 24(1):2561. PubMed ID: 39300437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase.
    Star K; Norén GN; Nordin K; Edwards IR
    Drug Saf; 2011 May; 34(5):415-28. PubMed ID: 21513364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
    Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
    Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.
    Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB
    Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An experimental investigation of masking in the US FDA adverse event reporting system database.
    Wang HW; Hochberg AM; Pearson RK; Hauben M
    Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures.
    Ang PS; Chen Z; Chan CL; Tai BC
    Expert Opin Drug Saf; 2016 May; 15(5):583-90. PubMed ID: 26996192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
    Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
    Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suspected adverse reactions reported for blood, blood components, and blood products in VigiBase.
    Samukange WT; Lu TA; Souverein PC; Gardarsdottir H; Mantel-Teeuwisse AK
    Transfusion; 2023 May; 63(5):982-992. PubMed ID: 36994873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of adverse drug reaction reports in South Africa: An analysis of VigiBase® for the year 2017.
    Steyn H
    S Afr Med J; 2023 Jun; 113(6):26-33. PubMed ID: 37278262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.
    Alroobaea R; Rubaiee S; Hanbazazah AS; Jahrami H; Garbarino S; Damiani G; Wu J; Bragazzi NL
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):4074-4081. PubMed ID: 35731078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
    Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
    Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
    Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
    Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.